Kineta Inc Stock Today
| KA Stock | 0.52 0.04 8.33% |
Performance0 of 100
| Odds Of DistressOver 84
|
Kineta is trading at 0.52 as of the 22nd of November 2024, a 8.33% up since the beginning of the trading day. The stock's open price was 0.48. Kineta has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Kineta Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of February 2016 | Category Healthcare | Classification Health Care |
Kineta is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 12.26 M outstanding shares of which 28.54 K shares are now sold short in the market by investors with about 0.68 days to cover all shorted shares. More on Kineta Inc
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Kineta Stock Highlights
| Chair CEO | Shawn Iadonato | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | KAS BANK N.V | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kineta can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kineta's financial leverage. It provides some insight into what part of Kineta's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kineta Inc (KA) is traded on NASDAQ Exchange in USA and employs 11 people. Kineta is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a market capitalization of 7.05 M. Kineta Inc is active under Biotechnology sector as part of Health Care industry. The entity has 12.26 M outstanding shares of which 28.54 K shares are now sold short in the market by investors with about 0.68 days to cover all shorted shares.
Kineta generates negative cash flow from operations
Check Kineta Probability Of Bankruptcy
Ownership AllocationKineta Inc holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Kineta Ownership Details
Kineta Inc Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Kineta market risk premium is the additional return an investor will receive from holding Kineta long position in a well-diversified portfolio.
| Mean Deviation | 5.1 | |||
| Semi Deviation | 7.08 | |||
| Standard Deviation | 8.13 | |||
| Variance | 66.08 |
Kineta Stock Against Markets
Kineta Corporate Management
| Gary Gentges | Executive Development | Profile | |
| Jacques Bouchy | Executive Development | Profile | |
| JD Esq | General Secretary | Profile | |
| Thierry Guillaudeux | Chief Officer | Profile | |
| Keith Baker | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kineta Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kineta. If investors know Kineta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kineta listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Quarterly Revenue Growth (1.00) | Return On Assets (1.14) | Return On Equity (3.69) |
The market value of Kineta Inc is measured differently than its book value, which is the value of Kineta that is recorded on the company's balance sheet. Investors also form their own opinion of Kineta's value that differs from its market value or its book value, called intrinsic value, which is Kineta's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kineta's market value can be influenced by many factors that don't directly affect Kineta's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kineta's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kineta is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kineta's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.